Michaela S Banck

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc The genomic landscape of small intestine neuroendocrine tumors
    Michaela S Banck
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Invest 123:2502-8. 2013
  2. pmc The ZNF217 oncogene is a candidate organizer of repressive histone modifiers
    Michaela S Banck
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Epigenetics 4:100-6. 2009
  3. pmc Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain
    Benjamin Storek
    Department of Medicine and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 105:1055-60. 2008
  4. pmc Diametrically opposite methylome-transcriptome relationships in high- and low-CpG promoter genes in postmitotic neural rat tissue
    Theresa Hartung
    Mayo Clinic, Rochester, MN, USA
    Epigenetics 7:421-8. 2012
  5. ncbi KLF6 degradation after apoptotic DNA damage
    Michaela S Banck
    Department of Medicine, Division of Hematology Oncology, P O Box 1079, Mount Sinai School of Medicine, One Gustave Levy Place, Room 24 42A, New York, NY 10029, USA
    FEBS Lett 580:6981-6. 2006
  6. doi Advances in small bowel neuroendocrine neoplasia
    Michaela S Banck
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Gastroenterol 30:163-7. 2014
  7. pmc Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats
    Benjamin Storek
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Mol Pain 2:4. 2006
  8. ncbi Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1
    Sharon Benzeno
    Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cancer Res 64:3885-91. 2004

Collaborators

Detail Information

Publications8

  1. pmc The genomic landscape of small intestine neuroendocrine tumors
    Michaela S Banck
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Invest 123:2502-8. 2013
    ..We conclude that sequencing-based analysis may provide provisional grouping of SI-NETs by therapeutic targets or deregulated pathways...
  2. pmc The ZNF217 oncogene is a candidate organizer of repressive histone modifiers
    Michaela S Banck
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Epigenetics 4:100-6. 2009
    ..Taken together, these findings suggest that ZNF217 assembles a distinct set of histone modifying proteins at target DNA sites that act synergistically in transcriptional repression...
  3. pmc Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain
    Benjamin Storek
    Department of Medicine and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 105:1055-60. 2008
    ..Therefore, gene transfer by LP may be suitable for developing gene therapy-based treatments for chronic pain...
  4. pmc Diametrically opposite methylome-transcriptome relationships in high- and low-CpG promoter genes in postmitotic neural rat tissue
    Theresa Hartung
    Mayo Clinic, Rochester, MN, USA
    Epigenetics 7:421-8. 2012
    ..Therefore, diametrically opposite methylome-transcriptome associations characterize LCP and HCP genes in postmitotic neural tissue in vivo...
  5. ncbi KLF6 degradation after apoptotic DNA damage
    Michaela S Banck
    Department of Medicine, Division of Hematology Oncology, P O Box 1079, Mount Sinai School of Medicine, One Gustave Levy Place, Room 24 42A, New York, NY 10029, USA
    FEBS Lett 580:6981-6. 2006
    ..KLF6 was unchanged by apoptosis via the extrinsic/death-receptor pathway. Deregulation of KLF6 stability may alter its tumor suppressor function and/or the response of tumors to chemotherapeutics...
  6. doi Advances in small bowel neuroendocrine neoplasia
    Michaela S Banck
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Gastroenterol 30:163-7. 2014
    ..This review aims at summarizing progress in clinical trials and basic science redefining the diagnosis and treatment of well differentiated small intestine neuroendocrine tumors (SI-NET)...
  7. pmc Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats
    Benjamin Storek
    Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Mol Pain 2:4. 2006
    ..Our studies focused on recombinant adeno-associated virus (rAAV), one of the most promising vector types for clinical use...
  8. ncbi Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1
    Sharon Benzeno
    Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cancer Res 64:3885-91. 2004
    ..Our data suggest that KLF6 converges with the Rb pathway to inhibit cyclin D1/cdk4 activity, resulting in growth suppression...